Research programme: diabetes insulin-device combinations - Medtronic/Sanofi

Drug Profile

Research programme: diabetes insulin-device combinations - Medtronic/Sanofi

Latest Information Update: 17 Jun 2014

Price : $50

At a glance

  • Originator Medtronic; Sanofi
  • Class Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase Unknown Diabetes mellitus

Most Recent Events

  • 14 Jun 2014 Investigation in Diabetes mellitus in USA (SC)
  • 14 Jun 2014 Investigation in Diabetes mellitus in Europe (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top